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Objective: Conﬂicting ﬁndings raise questions about the role of adiponectin in osteoarthritis (OA). The
current study aimed to investigate in OA patients the association between the production of adiponectin
and the grade of cartilage destruction, and to provide functional evidence for a potential role of adi-
ponectin in OA.
Design: The expression of adiponectin was examined by immunohistochemistry in cartilage obtained
from healthy individuals (n ¼ 2; ages 56 and 41 years; 1 male and 1 female) and OA patients (n ¼ 11; ages
64e79 years; 2 male and 9 female). The association between its production in chondrocytes and the
grade of cartilage destruction was established on full-depth cartilage biopsies. The functional activity of
adiponectin in OA cartilage was determined from the relation between the expression of adiponectin, its
receptor, cartilage-speciﬁc components and factors involved in matrix degradation, and from the
chondrocyte response to the full-length or the globular form of adiponectin.
Results: Adiponectin was not detected in healthy cartilage. Conversely, the adipokine was up-regulated
in damaged tissue, but no strong association with the grade of cartilage destruction was found. We
showed a positive correlation between adiponectin and mPGES or MMP-13 while AdipoR1 was related to
the expression of type 2 collagen, aggrecan and Sox9. The full-length form of adiponectin but not the
globular isoform, stimulated the production of PGE2 and MMP-13 activity in cultured human
chondrocytes.
Conclusions: The elevated level of adiponectin found in chondrocytes from OA patients might contribute
to matrix remodelling during OA, the full-length isoform being the single active form.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Although extensive studies aimed to identify the mechanisms
underlying articular cartilage changes associated with osteoar-
thritis (OA), the pathogenesis of this degenerative joint disease
remains unclear. It is well recognized that OA develops in the highly
metabolic and inﬂammatory environment of adiposity. In the lastto: N. Presle, UMR 7365
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s Research Society International. Pdecade, a new hypothesis based on the relation between obesity
and OA has emerged1. The sole role of biomechanical loading
cannot explain the increased risk for OA in non-weight-bearing
joints among overweight persons, and recent studies indicate
that adiposity rather than simply excess in body mass is detri-
mental to the joint2e5. More especially, some adipokines are
thought to be implicated in the development and the progression of
OA6. In fact, it is now well recognized that adipose tissue plays a
critical role as an active endocrine organ through the release of
various adipokines in an integrated network that maintains in-
teractions between fat and other organs. These adipose-derived
proteins are required for normal physiological homeostasis, but
impaired production may be involved in obesity-related disorders.
Adiponectin mediates its biological effects through two re-
ceptors, namely AdipoR1 and AdipoR27. This adipokine has a
modular structure comprising of an N-terminal collagenous
domainwith multiple collagen triple helix repeats, followed by a C-ublished by Elsevier Ltd. All rights reserved.
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pology with Tumor Necrosis Factor-a (TNFa)8,9. A truncated form of
adiponectin restricted to the globular domain can be generated by
leukocyte elastase secreted from activated monocytes and/or
neutrophils10. The adipokine exhibits insulin-sensitizing proper-
ties11 and reduced serum levels are found in obesity12. Adiponectin
is considered as an anti-inﬂammatory mediator especially with
regard to atherosclerosis13, but in some chronic inﬂammatory/
autoimmune diseases it may have pro-inﬂammatory effects and its
production correlates with inﬂammatory markers and disease ac-
tivity. Thus, serum adiponectin levels have been shown to be
strongly associated with radiographic changes in patients with
rheumatoid arthritis (RA)14 and to be predictive of radiographic
progression in early RA15. The adipokine was reported to stimulate
the production of IL-616, IL-817 and prostaglandin E2 (PGE2)18 by
human synovial ﬁbroblasts, suggesting its potential contribution to
the pathogenesis of synovitis in RA. Adiponectin may also be
considered as a marker of joint degradation or local inﬂammatory
processes. Indeed, increased serum levels of adiponectin were
detected in female patients with erosive compared with non-
erosive OA of the hands19. The adipokine is found in the synovial
ﬂuid of human OA-affected joints and its articular levels are posi-
tively correlated with degenerative fragments of aggrecan20.
Whether adiponectin plays a pro- or anti-inﬂammatory role in OA
is still the subject of debate and its effects on cartilage are far to be
fully elucidated. For Chen et al., adiponectin may have a protective
role on cartilage by up-regulating the Tissue Inhibitor of
Metalloproteinase-2 (TIMP-2) and down-regulating IL-1b-induced
MMP-1321. By contrast, the study of Lago et al. indicated that adi-
ponectin may trigger cartilage destruction through up-regulation
of MMPs and pro-inﬂammatory mediators22. The recent data
reporting the stimulating effect of adiponectin on the production of
chemokines, cytokines and matrix-degrading enzymes both in sy-
novial ﬁbroblasts and in chondrocytes further support the inﬂam-
matory and the destructive activity of adiponectin in the joint23e25.
In order to further understand the contribution of adiponectin
to cartilage changes associated with human OA, we investigated
the expression of adiponectin in cartilage obtained from OA pa-
tients in relation to the grade of cartilage destruction. We further
sought to identify the functional signiﬁcance of adiponectin
expression in chondrocytes. As AdipoR1 functions as a high-
afﬁnity receptor for globular and full-length adiponectin7 and is
strongly expressed in chondrocytes21, we determined whether
both forms of adiponectin are able to modulate inﬂammation and
cartilage destruction in OA.
Materials and methods
Patients and samples
Specimens of human OA articular cartilage were obtained from
tibial plateaus of patients undergoing total knee replacement sur-
gery (n ¼ 11; 2 male and 9 female; ages 64e79 years, mean
70.9  5.3 years; BMI 22e54 kg/m2, mean 33.0  8.8 kg/m2). All
patients were evaluated by an orthopaedic surgeon and diagnosed
for knee OA according to the criteria of the American College of
Rheumatology26. For comparison with diseased tissues, normal
knee joint cartilage was obtained from transplant donors (n ¼ 2;
ages 56 and 41 years; 1male and 1 female) through agreement with
the Agence de la Biomedecine. The human study described here
was conducted in conformity with the declaration of Helsinki
principles and was approved by the local Research Institution
(Commission de la Recherche Clinique; registration number UF
9607 e CPRC 2005). Written informed consent has been obtained
from all participants.After washing tibial plateaus in sterile phosphate buffered saline
(PBS), full-depth standardized cartilage biopsies (between 4 and 9
biopsies for each patient) were collected using a biopsy punch
(5 mm diameter). The samples were then cultured for 2 days at
37C in a humidiﬁed atmosphere of 5% CO2 in Dulbecco’s Modiﬁed
Eagle Medium/Nut Mix F12 (DMEM/Ham’s F12 medium) supple-
mented with L-glutamine (2 mM), penicillin (0.1 U/ml), strepto-
mycin (100 ng/ml) and amphotericin B (250 ng/ml). The tissue
specimens were thereafter ﬁxed for 24 h in 4% paraformaldehyde
and conditioned media were stored at 80C prior to analysis.
Adiponectin treatment of human chondrocytes
Cartilage samples collected from six OA patients were washed in
sterile phosphate buffer saline (PBS) and then cut into small pieces.
Chondrocytes were isolated after a sequential digestion of the
extracellular matrix with pronase (0.15%, w/v) for 2 h and colla-
genase (0.2%, w/v) overnight at 37C. After centrifugation, cells
were suspended in Dulbecco’sModiﬁed EaglesMedium/Ham’s F-12
(DMEM/Ham’s 12) supplemented with 10% (v/v) foetal calf serum
(FCS), 2 mM L-glutamine, penicillin (0.1 U/ml), streptomycin
(100 ng/ml) and 250 ng/ml amphotericin B (InVitrogen, Cergy-
Pontoise, France), then seeded as primary chondrocytes culture in
75 cm2 culture ﬂasks at high density (2  104 cells/cm2). They were
expanded for 10e12 days in monolayer in a humidiﬁed atmosphere
containing 5% CO2, and the culture mediumwas changed every 3e
4 days.
Conﬂuent primary chondrocytes were then incubated with
human recombinant full-length or globular adiponectin (R&D
Systems) at 0.2, 1 and 5 mg/ml for 24 h in 1% FCS containing me-
dium. The culture supernatants were then kept at 80C until
analysed.
Histological assessment
The full-length cartilage biopsies ﬁxed in paraformaldehyde
were decalciﬁed in rapid bone decalciﬁer (RDO, Eurobio, Les Ulys,
France) for 1 h, and further ﬁxed in 4% paraformaldehyde. Cartilage
specimens were then dehydrated in a graded series of alcohol and
embedded in parafﬁn.
For all cartilage samples, haematoxylineeosinesafran (HES),
and safranin-O-fast-green stainings were performed on serial sec-
tions (5 mm) to determine histological grading. The severity of OA
cartilage lesions was evaluated for each biopsy by two independent
observers, and was graded using the Mankin score27.
Immunohistochemical analysis
Parafﬁn sections (5 mm) from cartilage specimens were depar-
afﬁnized in Tissue Clear (Bayer Diagnostic, Puteaux, France) and
rehydrated in a graded series of ethanol. Antigen retrieval was
performed by heating the sections in a citrate buffer (10 mM,
pH ¼ 6) up to 60C for 30 min. The endogenous peroxidase activity
was blocked by incubating the sections in H2O2 (0.3%). After
neutralization of non-speciﬁc sites with bovine serum albumin
(BSA, 4% (w/v)) for at least 1.5 h, sections were incubated overnight
at 4C with a goat polyclonal antibody of the human adiponectin
(R&D Systems). After washing twice in PBS, the corresponding
biotinylated rabbit anti-goat IgG (Dako) was applied for 30 min at
room temperature. The signal was ampliﬁed with preformed
avidin-biotinylated horseradish peroxidase complexes for 45 min
at room temperature (EnVision kit, Dako), and staining was
developed with 3,30-diaminobenzidine (0.05% in hydrogen
peroxide). Counterstaining of nuclei was performed with haema-
toxylin, and sections were dehydrated in graded ethanol, cleared in
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primary antibody served as controls. The entire cartilage surface of
human biopsies was examined by two independent observers.
Gene expression analysis
Total ribonucleic acid (RNA) was extracted from freshly isolated
chondrocytes using the RNeasy Mini Kit (Qiagen, Courtaboeuf,
France) according to the manufacturer’s instructions. The integrity
of the isolated RNA was assessed by ethidium bromide staining on
agarose gel and concentrationwas determined bymeasurements of
the absorbance at 260 nm on a NanoDrop ND-1000 Spectropho-
tometer (Labtech, Palaiseau, France). RNA samples were then
reverse transcribed for 90 min at 37C using oligo-dT primers
(100 pmol) and M-MLV reverse transcriptase (200 U) (InVitrogen,
Cergy-Pontoise, France). Gene expression was analysed by quanti-
tative real-time polymerase chain reaction (PCR) (Lightcycler,
Roche, Mannheim, Germany) using the SYBRgreen master mix
system (Qiagen, Courtaboeuf, France) according to the manufac-
turer’s protocol. The gene-speciﬁc primer pairs optimized for this
method are described in Table I. As a control of the ampliﬁcation
speciﬁcity, melting curve analysis was performed for each PCR
experiment. Ampliﬁed products were also visualized by electro-
phoresis on a 2% agarose gel stained with ethidium bromide.
Quantiﬁcation was achieved using a speciﬁc calibration curve ob-
tained from serial dilutions of a PCR positive standardwith a known
amount of corresponding puriﬁed PCR products. For standardiza-
tion of gene expression levels, messenger RNA (mRNA) ratios
relative to RP29 chosen as housekeeping gene were calculated.
Release of adiponectin and PGE2
The concentrations of adiponectin in conditioned media of
cultured cartilage specimens were determined in duplicate by a
sandwich enzyme-linked immunosorbent assay (ELISA) using a
commercially available kit (R&D Systems, Lille, France). The con-
centrations of PGE2 released by untreated and adiponectin-
stimulated chondrocytes were also measured in duplicate by a
competitive enzyme immunoassay using commercially available
kit (R&D Systems, Lille, France). According to the manufacturer, the
detection limit was 250 pg/ml and 41.4 pg/ml for adiponectin and
PGE2 respectively. The interassay coefﬁcient of variation was 7.8%Table I
Sequences of primers and amplicon sizes
Gene Sequence Tm
(C)
Size
(bp)
RP29 Fwd AAG ATG GGT CAC CAG CAG CTC TAC TG 60 156
Rev AGA CGC GGC AAG AGC GAG AA
Adiponectin Fwd CCT AAG GGA GAC ATC GGT GA 57 173
Rev GTA AAG CGA ATG GGC ATG TT
AdipoR1 Fwd CTT CTA CTG CTC CCC ACA GC 63 196
Rev GAC AAA GCC CTC AGC GAT AG
AdipoR2 Fwd TCG CCC AAA TAT CTC CTT TG 60 199
Rev CCA AGG AAC AAA ACT TCC CAT A
Type 2 collagen Fwd ATG ACA ATC TGG CTG CCA 58 200
Rev CTT CAG GGC AGT GTA CGT
MMP-13 Fwd TGG TGG TGA TGA AGA TGA TTT G 57 125
Rev TCT AAG CCG AAG AAA GAC TGC
Sox9 Fwd AGC GAA CGC ACA TCA AGA C 60 160
Rev TGG TGG TCG GTG TAG TCG TA
Aggrecan Fwd TCG AGG ACA GCG AGG CC 61 85
Rev TCG AGG GTG TAG CGT GTA GAG A
mPGES Fwd AAC GAC ATG GAG ACC ATC TAC 60 314
Rev ACA TCA AGT CCC CAG GTA TAG CC
COX-2 Fwd GCT GGA ACA TGG AAT TAC CCA 58 98
Rev CTT TCT GTA CTG CGG GTG GAAand 10.6% for adiponectin and PGE2 respectively, and the intraassay
coefﬁcients of variation were less than 5%.
Determination of MMP-13 activity
MMP-13 activity was quantiﬁed in culture supernatants using a
ﬂuorogenic substrate. Brieﬂy, latent MMPs were activated by add-
ing 50 ml of culture supernatant to 50 ml of 1.5 mM 4-
aminophenylmercuric acetate (APMA (Sigma)) diluted in a Trise
HCl (50 mM, pH 7.5) reaction buffer containing 15 mM NaCl and
5 mM CaCl2. The ﬂuorogenic MMP-13 substrate MCA-Pro-Cha-Gly-
Nva-His-Ala-Dpa-NH2 (Calbiochem, Nottingham, UK) was then
added to a ﬁnal concentration of 10 mM. After 4 h of incubation in
darkness at 37C, MMP-13-induced cleavage of the substrate was
measured with a Fluostar Optima spectroﬂuorimeter (BMG Lab-
technologies, Champigny-sur-Marne, France) at excitation and
emission wavelengths of 325 nm and 393 nm, respectively. Data
were expressed in arbitrary units of ﬂuorescence.
Statistical analysis
Statistical analysis was conducted with SPSS software (SPSS Inc.,
Chicago, IL, USA). In order to study the release of adiponectin from
OA cartilage in relation to the grade of cartilage destruction, 84
biopsies were collected from 11 OA patients. The samples were split
up into two subgroups according to the BMI of the patients (n ¼ 37
biopsies for BMI < 30 kg/m2 and n ¼ 47 biopsies for BMI  30 kg/
m2). The statistical analysis was performed by comparing the pro-
duction of adiponectin for each histological score (mild, moderate
and severe). As the data did not fulﬁl the assumption of a normal
distribution implicit in the analysis of variance, Friedman repeated
measures analysis of variance on ranks was used to compare
median-values of the three histological groups of cartilage
destruction. When this global-test was statistically signiﬁcant
(P < 0.05), a pair-wise post-hoc analysis was performed. For these
tests, the power analysis included a post-hoc pair-wise correction
(0.0167) as a control for alpha inﬂation.
The analysis of statistical correlation between the expression of
adiponectin or its receptor AdipoR1 (independent variables) and
that of genes encoding cartilage matrix components or inﬂamma-
tory factors (dependent variables) were performed with chon-
drocytes freshly isolated from the 11 OA patients by the Spearman
test of rank correlation.
The effect of adiponectin on cultured chondrocytes was exam-
ined with cells isolated from six OA patients and experiments were
performed in triplicate for each patient. Statistical differences be-
tween adiponectin-treated and untreated chondrocytes were
determined with mean-values obtained from the triplicate exper-
iments (n ¼ 6) using one-way analysis of variance (ANOVA) fol-
lowed by a Student’s t test. P value less than 0.05 was considered
signiﬁcant for differences and correlations.
Results
Relationship between adiponectin expression and the grade of
cartilage destruction
Before examining the grade-dependent expression of adipo-
nectin in OA cartilage, we compared healthy human articular
cartilage with articular cartilage obtained from OA patients. No
adiponectin immunostaining was detected in normal cartilage
whereas many adiponectin positive chondrocytes were found in OA
cartilage [Fig. 1(A)]. Adiponectin expressionwas most prominent in
superﬁcial and middle zones of OA cartilage, but rarely found in the
deep layer.
AB
Fig. 1. Association between the synthesis of adiponectin and cartilage degradation. A. Production of adiponectin in representative sections from cartilage biopsies obtained in
healthy individuals and OA patients. The control staining was performed without primary antibody. Positive cells are coloured brown and nuclei are counterstained with
haematoxylin (original magniﬁcation 40). B. BMI-dependent association between the production of adiponectin and the grade of cartilage destruction. Full-depth cartilage bi-
opsies (n ¼ 84) obtained from 11 OA patients were cultured for 48 h and then histologically graded according to the Mankin score. Adiponectin production was determined in
duplicate for each cartilage sample. Horizontal lines indicate means with 95% conﬁdence intervals and each dot represents one cartilage specimen.
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prompted us to determine whether the adipokine level was asso-
ciated with the grade of cartilage destruction. Five to nine full-
depth standardized cartilage biopsies were sampled in tibial pla-
teaus collected from 11 OA patients (n ¼ 84). The production of
adiponectin was determined by ELISA in conditioned media from
cultured tissue samples to improve the quantitative analysis of
adiponectin expression compared to immunohistochemical score.
At the end of the culture period, each specimen was stained with
safranin-O-fast-green to evaluate the severity of OA cartilage lesion.
Cartilage samples exhibited variability in their histological
appearance ranging from surface irregularities to marked middle
cracks. Proteoglycan loss was evident histologically in moderately
damaged OA samples, but the overall thickness of the cartilage
was preserved. By contrast, specimens with advanced cartilage
destruction, exhibited a severe proteoglycans loss and cartilage
erosion. Overall, 84 biopsies were divided into three groups
according to the histological severity grade: Mankin scores
between 1e4, 5e9 and 10e14 were considered as mild (n ¼ 18),
moderate (n ¼ 44) and severe OA (n ¼ 22), respectively. In
addition, two groups of patients were considered according to the
BMI values (obese vs non-obese patients). Our data indicated that
a grade-dependent increase in the production of adiponectin was
found for non-obese patients (BMI < 30 kg/m2, n ¼ 5), but the
difference did not reach statistical signiﬁcance [Fig. 1(B)]. For obese
patients (BMI  30 kg/m2, n ¼ 6), specimens with mild OA dis-
played reduced levels of adiponectin when compared to sampleswith moderate (P ¼ 0.0075) or severe (P ¼ 0.0103) OA histological
score. However, the synthesis of adiponectin did not increase
anymore for the most severe OA grade.
Associations between adiponectin, its receptors and extracellular
matrix, degradative enzymes and inﬂammatory mediators
The potential pathophysiological role of adiponectin in OA
cartilage was evaluated through the relationships between the
mRNA levels of the genes encoding adiponectin or its receptors
(AdipoR1 and AdipoR2) on one hand, and aggrecan, type 2 collagen,
Sox9, MMP-13, mPGES and iNOS on the other hand. The correlation
analysis revealed a signiﬁcant positive association between the
mRNA levels of adiponectin and those of mPGES orMMP-13 [Fig. 2].
By contrast, no relationship was found between adiponectin and
the cartilage-speciﬁc genes. As AdipoR2 was barely detected in
chondrocytes from OA patients, the associations have been exam-
ined with AdipoR1. Unlike the associations found with adiponectin,
we failed to demonstrate any correlation between the mRNA levels
of AdipoR1 and mPGES or MMP-13 whereas aggrecan, Sox9 and
type 2 collagen were strongly related to the gene expression of the
receptor [Fig. 3].
Effects of adiponectin on chondrocytes
To determine whether the correlations previously found in
freshly isolated chondrocytes obtained from OA patients are causal
Fig. 2. Correlations between the mRNA expression of adiponectin and that of the microsomal prostaglandin E synthase (mPGES), the matrix metalloprotease-13 (MMP-13), the
aggrecan, Sox9 and collagen type 2 in cartilage from OA patients (n ¼ 11).
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Fig. 3. Correlations between the mRNA expression of adiponectin receptor 1 (AdipoR1) and that of the microsomal prostaglandin E synthase (mPGES), the matrix metalloprotease-
13 (MMP-13), the aggrecan, Sox9 and collagen type 2 in cartilage from OA patients (n ¼ 11).
P.-J. Francin et al. / Osteoarthritis and Cartilage 22 (2014) 519e526 523relationships, we next investigated whether the adipokine as its
full-length or globular form was able to modulate inﬂammation or
catabolic activity in chondrocyte. For more physiological relevance,
the recombinant protein was used at concentrations found in the
synovial ﬂuid fromOA patients (0.2,1 and 5 mg/ml)28. Immunoassay
analysis of culture supernatants indicated that stimulation of pri-
mary human chondrocytes with the highest dose of the full-length
adiponectin increased the MMP-13 activity (P < 0.001) and thePGE2 synthesis (P ¼ 0.0012) [Fig. 4]. By contrast, neither the lower
concentrations nor the globular form of adiponectin did not induce
any signiﬁcant changes in MMP-13 activity and PGE2 production. In
all experimental conditions, no detectable amount of NOwas found
in the culture supernatant of adiponectin-stimulated chondrocytes.
The lack of any response in chondrocytes treated with heat-
inactivated adiponectin indicated that endotoxins did not account
for the stimulatory effect of adiponectin.
Fig. 4. Dose-dependent effect of the full-length or the globular form of adiponectin on
the activity of the matrix metalloprotease-13 (MMP-13) and the prostaglandin E2
(PGE2) production in chondrocytes collected from six OA patients. Experiment was
carried out in triplicate for each patient. Horizontal lines indicate means with 95%
conﬁdence intervals and each dot represents the data found with the chondrocytes
from one patient. * ¼ P < 0.05 between adiponectin-treated and unstimulated chon-
drocytes with n ¼ 6.
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It is now well established that chondrocytes produce various
adipokines including adiponectin. This adipose-derived protein is
found in the synovial ﬂuid of OA patients, but its activity in the joint
remains unclear. Elevated serum levels of adiponectin are found in
patients with the radiologically most severe OA25 and in patients
with erosive compared with non-erosive OA of the hand19.
Conversely, a higher level of adiponectin has been associated with a
lower risk for hand OA progression29, and knee OA patients with
higher radiographic severity had signiﬁcantly lower adiponectin
levels in both plasma and synovial ﬂuid30. The stimulatory effect of
adiponectin on the production of NO, IL-6, MMP-1 and MMP-3 in
primary human chondrocytes25 as well as the elevated level of
collagenase-cleaved type 2 collagen neoepitope found in the cul-
ture media from adiponectin-stimulated cartilage samples31 sug-
gest that adiponectin may actively participate in cartilage matrix
degradation in OA. However, the adipokinewas also reported to up-
regulate the expression of mRNAs encoding type 2 collagen, Sox9
and aggrecan32.Adiponectin is up-regulated in OA chondrocytes, but without strong
association with the grade of cartilage destruction
We report here the ﬁrst demonstration of the expression of adi-
ponectin at sites of cartilage destruction. Indeed, the adipokine is not
detected in healthy cartilage, but is up-regulated in damaged tissue.
However, ELISA measurements which provide quantitatively accu-
rate information on adiponectin levels in cultured OA cartilage su-
pernatants indicate that the increase in adiponectin production
depends on the BMI of the patients and is not strongly related to
the grade of cartilage destruction. A statistically signiﬁcant
increase is found only in specimens obtained from patients with
BMI  30 kg/m2. Cartilage samples with moderate lesions and
collected from obese OA patients release high amounts of adipo-
nectin, but the production does not increase anymore when damageare getting worse. As was previously shown for RA14, these ﬁndings
suggest that adiponectin may play different physiopathological roles
depending on the stages of OA. The adipokine may be more associ-
ated with cartilage destruction in patients with established disease
compared with those with early OA, obesity being an aggravating
factor. The current data provide somewhat conﬂicting information
over previous data published by Koskinen et al.25. They showed a
positive association between radiological OA severity and the
amount of adiponectin released by OA cartilage samples in culture
media. Variations in the study design, and more especially in the
index severity used to investigate the link with adiponectin pro-
duction, might explain this discrepancy. Indeed, the current study
looked for cartilage damage through histological grading by the
Mankin score while Koskinen et al. referred to a radiological score of
thewhole joint to evaluate OA. In addition, these authors studied OA
patients undergoing knee replacement surgery indicating that the
range of OA severity includes only severe OA. We assumed actually
that our experimental approach based on measurements performed
with an individual sample is more suitable to establish the relation
between adiponectin production and cartilage changes. Our data
reveal actually that various cartilage specimens obtained from a
single joint produce different amounts of adiponectin, suggesting
that adiponectin levels in cultured cartilage supernatant cannot be
related to an overall radiological score.
The full-length form of adiponectin exhibits inﬂammatory and
destructive activities for cartilage
Because of the up-regulation of adiponectin in OA cartilage
compared to healthy tissue, we next sought to elucidate its po-
tential contribution in OA by examining the effect of both adipo-
nectin isoforms on chondrocyte function. Studying the globular
form is essential as especially this isoform has a high-binding af-
ﬁnity for AdipoR1 which is strongly expressed in human OA
cartilage.
In accordance with previous studies, we showed that adipo-
nectin stimulates MMP-13 activity. Our data indicated also that the
adipokine increases the production of PGE2 in chondrocytes, as was
previously demonstrated upon exposure of synovial ﬁbroblasts to
adiponectin18. Interestingly, this stimulatory effect of adiponectin
on MMP-13 activity and PGE2 release matches well with the posi-
tive association found in the current study between the mRNA
expression in freshly isolated OA chondrocytes of adiponectin and
that of MMP-13 and mPGES. The pro-inﬂammatory effect of adi-
ponectin has been previously observed in human synovial ﬁbro-
blasts. Thus, the adipokine stimulates the production of
chemokines and cytokines16,23,33, and human synovial ﬁbroblasts
increase the protein secretion of proMMP-1, MMP-3, MMP-10 and
MMP-12 in response to adiponectin24. Beside, the adipokine up-
regulates numerous MMPs in human chondrocytes including
MMP-1, -3, -1331,25, and increases the release of collagenase-
cleaved type 2 collagen neoepitope from adiponectin-stimulated
cartilage samples31. All these ﬁndings support the role of adipo-
nectin in inﬂammation through the activation and recruitment of
inﬂammatory cells into the joint, and in cartilage destruction. Be-
side, we showed for the ﬁrst time that the globular form is unable
to induce any response in human chondrocyte, suggesting that the
potential pro-inﬂammatory effect of adiponectin is due to the full-
length form only.
The expression of AdipoR1 in OA cartilage is strongly associated with
that of matrix components
Most studies assign to adiponectin destructive effects, but very
few examined its potential contribution to the synthesis of
P.-J. Francin et al. / Osteoarthritis and Cartilage 22 (2014) 519e526 525extracellular matrix. Delessa Challa et al.32 demonstrated that adi-
ponectin up-regulates the expression of type 2 collagen, aggrecan
and Sox9 in cultured chondrocytes. Surprisingly, our data indicate
that the expression of these genes in OA cartilage is not associated
with adiponectin but rather with the mRNA levels of its receptor
AdipoR1. The elevated levels of AdipoR1 found in damaged carti-
lage area compared to non-lesional area31 suggest that adiponectin
may be involved in the repair attempts induced by cartilage
destruction during OA. The adipokine might also contribute to the
chondrocyte hypertrophy-like changes observed during OA. A
phenotypic shift in the mature chondrocyte to a cell type that
displays many characteristics of hypertrophic cells is a typical
feature of OA and is associated with the progressive cartilage
breakdown34. The adiponectin-mediated increase in the mRNA
expression of type 2 collagen, aggrecan and Sox9, as well as its
stimulatory effect on Runx2 and type 10 collagen found by Challa
et al.32 suggest that adiponectin may drive chondrocyte changes
towards the hypertrophic stage.
As discussed above, the strength of the current study is the use
of individual cartilage specimens to establish, on the same sample,
the link between the production of adiponectin and the grade of
cartilage degradation. This experimental approach has however
some limitations especially when considering the OA disease. First,
the different grades of cartilage destruction cannot be extrapolated
to the different stages of the disease. Adiponectin might be better
related to OA severity if both the synovial ﬂuid level and an overall
OA score are determined. Second, a cartilage sample with severe
damage may locally inﬂuence the release of adiponectin from a
neighbouring specimen with a lower Mankin score.
Conclusions
In summary, the current study provides further insights on the
production of adiponectin in human OA cartilage. The adipokine is
not detected in healthy tissue but is up-regulated in cartilage from
OA patients. The close correlation found in OA cartilage between
the expression of the gene encoding adiponectin and that of the
genes encoding mPGES and MMP-13, as well as the stimulatory
effect of physiological concentrations of the full-length adipo-
nectin, but not the globular form, on the production of PGE2 and
MMP-13 activity, further support the role of this adipokine in
cartilage destruction. However, our data demonstrated also that the
mRNA level of AdipoR1 is strongly associated with the mRNA
expression of cartilage-speciﬁc components, suggesting that adi-
ponectin is rather involved in matrix remodelling. The lack of any
strong association between the production of adiponectin and the
grade of cartilage destruction may explain the discrepancies
observed in the various studies dealing with the relation between
the adiponectin levels and the severity of the disease. Further in-
vestigations on the expression of adiponectin and its receptors
during the course of experimental models of OAwould be helpful to
determine whether the adipokine is protective in mild or moderate
OA and actively participate in the process of cartilage degradation
in severe OA, depending partly on the expression of AdipoR1.
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